- Home
- MDWD vs NMG Comparison
MDWD vs NMG Comparison
Compare MDWD & NMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- NMG
- Stock Information
- Founded
- MDWD 2000
- NMG 2011
- Country
- MDWD Israel
- NMG Canada
- Employees
- MDWD N/A
- NMG N/A
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- NMG Other Metals and Minerals
- Sector
- MDWD Health Care
- NMG Basic Materials
- Exchange
- MDWD Nasdaq
- NMG Nasdaq
- Market Cap
- MDWD 208.2M
- NMG 249.7M
- IPO Year
- MDWD 2014
- NMG 2017
- Fundamental
- Price
- MDWD $20.52
- NMG $1.67
- Analyst Decision
- MDWD Strong Buy
- NMG Strong Buy
- Analyst Count
- MDWD 2
- NMG 2
- Target Price
- MDWD $35.00
- NMG $2.58
- AVG Volume (30 Days)
- MDWD 48.8K
- NMG 37.2K
- Earning Date
- MDWD 08-13-2025
- NMG 08-13-2025
- Dividend Yield
- MDWD N/A
- NMG N/A
- EPS Growth
- MDWD N/A
- NMG N/A
- EPS
- MDWD N/A
- NMG N/A
- Revenue
- MDWD $19,213,000.00
- NMG N/A
- Revenue This Year
- MDWD $20.80
- NMG N/A
- Revenue Next Year
- MDWD $26.92
- NMG N/A
- P/E Ratio
- MDWD N/A
- NMG N/A
- Revenue Growth
- MDWD N/A
- NMG N/A
- 52 Week Low
- MDWD $14.14
- NMG $1.22
- 52 Week High
- MDWD $22.51
- NMG $2.58
- Technical
- Relative Strength Index (RSI)
- MDWD 50.69
- NMG 45.58
- Support Level
- MDWD $19.07
- NMG $1.63
- Resistance Level
- MDWD $19.55
- NMG $1.67
- Average True Range (ATR)
- MDWD 0.56
- NMG 0.05
- MACD
- MDWD -0.03
- NMG 0.00
- Stochastic Oscillator
- MDWD 88.89
- NMG 41.18
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
About NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The company currently operates in two segments: the Matawinie Mine Project and the Battery Material Plant project.